Despite promising to be “tough on China, a new report from Insider highlights that Pennsylvania Republican U.S Senate nominee Mehmet Oz has a long record of praising the country, and “taking a business-like approach to his relationships with them.”
According to the report, Oz’s “hardline sentiments toward China weren’t always so.” In 2013, Oz praised a business venture with Neusoft — one of China’s largest software outsourcing providers. The partnership was even celebrated in a newsletter that “trumpeted [the] Oz-Neusoft union.”
But this wasn’t Oz’s first foray into the country. Before scamming Pennsylvanians, Oz was scamming consumers with products made overseas, largely in China. Moreover, Oz had a lucrative sponsorship deal with Usana Health Sciences — a multi-level marketing firm “whose largest single market is China.”
Oz’s campaign trail rhetoric has repeatedly been exposed as effectively fraudulent and at odds with his actual record. Time and time again, he has proven that he will say and do anything to get elected, no matter how big the lie.
By: Dave Levinthal | August 23, 2022
Key Points:
- “Throughout his US Senate campaign in Pennsylvania, Republican candidate Mehmet Oz has reserved some of his strongest criticism for China — and those who’d court the communist nation.”
- “And Oz castigated his now-vanquished Republican primary opponent, Dave McCormick, whom he defeated by fewer than 1,000 votes, as ‘the China first candidate in the race’ — a knock on McCormick’s overseas business dealings.”
- “But a buzz-wordy press release issued nearly a decade ago by Neusoft Xikang, a healthcare technology subsidiary of Chinese software and information technology giant Neusoft Corporation, suggests Oz’s hardline sentiments toward China weren’t always so.”
- “Rather, Oz — a media-personality-turned-Donald Trump-endorsed politician struggling to keep pace with Democrat John Fetterman in Pennsylvania’s US Senate race — celebrated his new ‘partnership’ in China.”
Read the full report here.
Published: Aug 23, 2022 | Last Modified: Aug 28, 2022